Perspectives on why DanGer Shock is the first positive trial on mechanical circulatory support in cardiogenic shock
Heart Failure Reviews · 2024
DOI: 10.1007/s10741-024-10470-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Heart Failure Reviews, 2024. Verfasst von Giulio M Mondellini und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Cardiology, Cardiovascular Institute, Erasmus University Medical Center Rotterdam, Office Nt-645, Dr. Molewaterplein 40,…. Hauptthemen laut MEDLINE: Extracorporeal Membrane Oxygenation, Heart-Assist Devices, Myocardial Infarction, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Cardiogenic shock related to acute myocardial infarction (AMI-CS) remains a severe condition associated with a high risk of mortality despite increased availability of primary percutaneous coronary intervention and improvements in pharmacologic and device-based therapy. The results of the DanGer Shock trial stand out compared with the outcomes of the previous trials and mark the first mechanical circulatory support (MCS) strategy to show a benefit in patients with AMI-CS, a population that has always been challenging to study. Notably, negative findings from previous trials may mask positive treatment effects in specific subgroups and patient category. We systematically reviewed the design of all contemporary randomized controlled AMI-CS trials and identified four distinct features, which likely provide reasons why DanGer Shock became the first positive randomized controlled trial to support MCS in AMI-CS. DanGer Shock was the first RCT that established MCS in the context of AMI-CS. Key features were (1) patient phenotype that 1) includes STEMI and 2) excludes severe RV failure and persistent comatose state after out-of-hospital cardiac arrest; (3) optimal timing of MCS deployment, as soon as possible (lower SCAI stage) and before revascularization efforts; and (4) rigorous intensive care management protocols on hemodynamic and MCS monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Interventional Cardiology, Cardiovascular Institute, Erasmus University Medical Center Rotterdam, Office Nt-645, Dr. Molewaterplein 40, Thoraxcenter, Rotterdam, 3015 GD, The Netherlands.
- Department of Interventional Cardiology, Cardiovascular Institute, Erasmus University Medical Center Rotterdam, Office Nt-645, Dr. Molewaterplein 40, Thoraxcenter, Rotterdam, 3015 GD, The Netherlands. n.vanmieghem@erasm…
ORCID-Profile: Nicolas M Van Mieghem
Zitieren
APA
Mondellini, G. M., van den Enden, A. J. M., & Van Mieghem, N. M. (2024). Perspectives on why DanGer Shock is the first positive trial on mechanical circulatory support in cardiogenic shock. Heart Failure Reviews. https://doi.org/10.1007/s10741-024-10470-2
Vancouver
Mondellini GM, van den Enden AJM, Van Mieghem NM. Perspectives on why DanGer Shock is the first positive trial on mechanical circulatory support in cardiogenic shock. Heart Failure Reviews. 2024. doi:10.1007/s10741-024-10470-2
BibTeX
@article{Mondellini2024,
author = {Mondellini, Giulio M and van den Enden, Antoon J M and Van Mieghem, Nicolas M},
title = {Perspectives on why DanGer Shock is the first positive trial on mechanical circulatory support in cardiogenic shock},
journal = {Heart Failure Reviews},
year = {2024},
doi = {10.1007/s10741-024-10470-2}
}
EUVIMED